Glaukos Corporation Common Stock (NY:GKOS)

126.82 +8.12 (+6.84%)

Streaming Delayed Price Updated: 10:58 AM EST, Jan 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Why Are Glaukos Shares Rallying Today? ↗

November 03, 2021

Glaukos Corporation (NYSE: GKOS) shares have gained as investors cheer the final physician payment rates and outpatient facility fees issued by the Centers for Medicare...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2021 ↗

November 03, 2021

Upgrades Benchmark upgraded the previous rating for Devon Energy Corp (NYSE:

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 03, 2021

Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion...

Via Benzinga

Why Glaukos Shares Dipped Today ↗

July 20, 2021

Glaukos (NYSE:GKOS) shares are trading lower after Wells Far...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

November 03, 2021

Good morning, trader! We're starting the day off right with a dive into the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

25 Stocks Moving in Wednesday's Pre-Market Session ↗

November 03, 2021

Gainers Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 56.4% to $26.20 in pre-market trading on the heels of three new announcements from the company outlining strategic plans to...

Via Benzinga

Glaukos Corporation to Release Third Quarter 2021 Financial Results after Market Close on November 4

October 14, 2021

From Glaukos Corporation

Via Business Wire

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology ↗

October 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...

Via Benzinga

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 European Society of Cataract and Refractive Surgeons Annual Meeting

October 07, 2021

From Glaukos Corporation

Via Business Wire

Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.

September 20, 2021

From Glaukos Corporation

Via Business Wire

Ivantis To Pay $60M In Patent Litigation Settlement With Glaukos ↗

September 15, 2021

Glaukos Corp (NYSE:GKOS) has

Via Benzinga

Topics Intellectual Property

Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc.

September 15, 2021

From Glaukos Corporation

Via Business Wire

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗

October 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout ↗

October 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (...

Via Benzinga

Glaukos Files Pre-Market Application For Intraocular Pressure Device ↗

September 03, 2021

Glaukos Corp (NYSE: GKOS) has submitted a supplemental premarket approval (PMA) application to the FDA for its iStent infinite Trabecular Micro-Bypass System....

Via Benzinga

Glaukos Announces Submission of Supplemental Pre-Market Approval Application for iStent infinite™

September 03, 2021

From Glaukos Corporation

Via Business Wire

Return on Capital Employed Overview: Glaukos ↗

September 01, 2021

Pulled from Benzinga Pro data Glaukos (NYSE:GKOS) reported Q2 sales of $78.09 million. Earnings fell to a loss of $14.22 million, resulting in a 20.47% decrease from last quarter...

Via Benzinga

Glaukos Announces Participation in the Wells Fargo Healthcare Conference

August 26, 2021

From Glaukos Corporation

Via Business Wire

Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent® Technologies

August 23, 2021

From Glaukos Corporation

Via Business Wire

Glaukos Guided Below Consensus After Q2 Earnings; Analysts Cut Price Target ↗

August 06, 2021

Glaukos Corporation (NYSE:GKOS)

Via Benzinga

Glaukos Corp (GKOS) Q2 2021 Earnings Call Transcript ↗

August 06, 2021

GKOS earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Glaukos Corporation Announces Second Quarter 2021 Financial Results

August 05, 2021

From Glaukos Corporation

Via Business Wire

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting

July 22, 2021

From Glaukos Corporation

Via Business Wire

Why Glaukos Stock Sank Today ↗

July 20, 2021

An analyst downgraded the healthcare stock.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2021 ↗

July 26, 2021

Upgrades Tudor Pickering upgraded the previous rating for Precision Drilling Corp (NYSE:

Via Benzinga

62 Biggest Movers From Yesterday ↗

July 21, 2021

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares surged 208% to settle at $10.04 on Tuesday as the company said it received FDA breakthrough device designation for the treatment...

Via Benzinga

Wells Fargo Downgrades Glaukos To Sell On iStent Reimbursement Cuts ↗

July 20, 2021

Wells Fargo analyst Lawrence Biegelsen downgraded Glaukos to Underweight from Equal Weight with a price target of $41, down from $100.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2021 ↗

July 20, 2021

Upgrades For Bank of Marin Bancorp (NASDAQ:

Via Benzinga

Glaukos Corporation to Release Second Quarter 2021 Financial Results after Market Close on August 5

July 15, 2021

From Glaukos Corporation

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.